H eart failure (HF) is associated with high morbidity and mortality, 1 but prognosis can vary significantly between individual patients. Accurate risk stratification is important for understanding patient factors associated with poor outcomes and, by extension, communicating expectations with patients, identifying potential targets for intervention, tailoring the intensity of care decisions, and creating risk-standardized outcomes measures. 2
groups of left ventricular systolic function should provide needed clarity to the field of HF risk prediction. Therefore, the objective of this study was to model a common set of demographic and clinical characteristics across categories of LVEF for predicting death and hospitalization in a large, multicenter, community-based, contemporary cohort of adults with HF.
Methods

Patients
The Cardiovascular Research Network served as the source population. 13 Participating sites for the current analysis were Kaiser Permanente Northern California, Kaiser Permanente Colorado, Kaiser Permanente Northwest, and the Fallon Community Health Plan. 14 
Covariates
Assessments of left ventricular systolic function were ascertained for each HF patient from echocardiograms, radionuclide scintigraphy, other nuclear imaging modalities, and left ventriculography test results available from site-specific databases complemented by manual chart review. We defined 3 categories of left ventricular systolic function: preserved (HF-PEF) as a reported quantitative LVEF ≥50% or a physician's qualitative assessment of preserved or normal LVEF; borderline reduced (HF-BREF) as LVEF 41% to 49% or mildly decreased; and reduced (HF-REF) as LVEF ≤40% or moderately or severely reduced. 19 If the quantitative and qualitative assessments disagreed, the summary qualitative measure was used. The measure obtained closest to but after the index date of study entry was used.
Patients without a documented LVEF measurement were excluded from the cohort (n=6998; 18.9%).
Variables included in the respective models were chosen a priori on the basis of previously published HF prognostic models [3] [4] [5] [6] [7] [8] [9] and availability within the virtual data warehouse (VDW). We determined the presence of coexisting illnesses on the basis of diagnoses or procedures using relevant ICD-9 codes, laboratory results, or filled outpatient prescriptions from health plan databases, as well as site-specific diabetes mellitus and cancer registries. We collected baseline and follow-up data on diagnoses and procedures on the basis of previously described ICD-9 codes and current procedural terminology procedure codes. 20 We ascertained available ambulatory results for blood pressure, cholesterol measurements, and hemoglobin level on or before the index hospitalization and during follow-up from health plan ambulatory visit and laboratory databases. Some potentially available factors known to correspond with risk were, nonetheless, excluded because of technical issues. Covariates notably missing from model construction included medication use, serum natriuretic peptide levels, and measures of renal function.
Outcomes
Deaths were identified from hospital and billing claims databases, administrative health plan databases, state death certificate registries, and Social Security Administration files as available at each site. These approaches have yielded >97% vital status information in prior studies. 14, 17 Hospitalizations were determined from each site's VDW. Hospitalizations for HF were identified from each site's VDW on the basis of a primary discharge diagnosis for HF using the same inclusion criteria ICD-9 codes described previously.
Statistical Analysis
All analyses were conducted using SAS statistical software, version 9.1 (Cary, NC). We characterized baseline patient demographic and clinical characteristics stratified by LVEF categories. Continuous variables were categorized using cut points chosen based on clinically meaningful values. Missing covariate data for continuous variables were treated as a separate category. Because of large sample size, in addition to P values, we also calculated D values from the standardized difference between mean values across LVEF strata to compare the magnitude of difference between groups. We considered a value of D>0.1 to signify a meaningful difference. We constructed multivariable extended Cox regression models for each outcome stratified by LVEF category. All variables listed in Table 1 were considered for model inclusion and those with a P value of ≤0.2 at baseline comparison for each outcome within each LVEF strata were included in the final regression model. Subjects were censored at the time they disenrolled from the health plan or reached the end of study follow-up on December 31, 2008; patients were also censored at the time of death for hospitalization models. We applied a robust sandwich estimator to account for clustering of multiple observations within the same subject and explored whether additional adjustment for clustering at the site level was necessary.
To assess whether the association of a potential predictor variable differed based on LVEF category, we calculated interaction model results for HF-PEF versus HF-REF and separately for HF-BREF versus HF-REF for each of the 3 outcomes. To maintain simplicity for interpretation, we dichotomized categorical variables at the median value. We calculated P values and hazard ratios associated with each interaction (eg, sex×LVEF category) for the outcome of interest. Because of the systematic nature of the analysis thereby creating multiple comparisons, we chose to highlight only those interactions with a P value of <0.01 (recognizing that a highly conservative Bonferroni correction for ≈150 tests of interaction would use a P value of 0.0003 for significance).
Results
We identified 30 094 adults with HF. Their mean age was 74 years, and 46% were women (Table 1) . Overall, 49.5% of patients had HF-PEF, 16.2% had HF-BREF, and the remaining 34.3% had HF-REF. There was a high burden of comorbidity across all LVEF categories. Median follow-up was 1.8 years (interquartile range, 0.8-3.1). During follow-up, 8060 (26.8%) patients died, 8108 (26.9%) were hospitalized for HF, and 20 272 (67.4%) were hospitalized for any reason. In comparison with the study cohort, patients excluded because of absence of an LVEF measure were older (mean age, 75.6 versus 73.7 years; P<0.001), more often white (78.9% versus 75.3%; P<0.001), trended toward more often women (47.3% versus 46.0%; P=0.06), had more prevalent HF (73.0% versus 60.1%; P<0.001), had less myocardial infarction (12.3 versus 13.9%), and generally had more comorbidity, including cerebrovascular disease (23.0% versus 21.1%; P<0.001), diabetes mellitus (26.2% versus 24.0%; P<0.001), dementia (10.0% versus 7.3%; P<0.001), and chronic lung disease (43.3% versus 41.1%); during follow-up there was no significant difference between death (27.8% for those without a measure of LVEF; P=0.08) but had lower rates of HF hospitalization (22.6%; P<0.001) and all-cause hospitalization (63.4%; P<0.001).
In multivariable Cox models for all-cause death ( Figure  [A] ), advanced age and severe anemia showed the strongest association with the outcome across all strata of LVEF (recognizing that models did not include a measure of renal function). Only systolic blood pressures <100 mm Hg showed significant association with increased mortality. Past medical history factors were either neutral or weakly associated with death, except for prior coronary revascularization, which was associated with survival.
In multivariable models for hospitalization from HF (Figure  [B] ), advanced age and anemia continued to be strong predictors of the outcome across all strata of LVEF. Only patients aged >85 years seemed to have a significantly increased risk of HF hospitalization. Hypertension, more than hypotension, was predictive of HF hospitalization. A variety of medical history carried small increased risk of HF hospitalization; notably prior coronary revascularization was not associated with hospitalization from HF.
Multivariable models for all-cause hospitalization ( Figure  [C] ) were quite similar to those for HF hospitalization, despite the majority of all-cause admissions having a non-HF primary discharge diagnosis code. Anemia continued to show the largest adjusted hazards ratios for the outcome. Progressive hypertension was increasingly predictive of all-cause hospitalization; systolic blood pressure <100 mm Hg was also associated with an increase in all-cause hospitalization, creating a U-shaped association for systolic blood pressure overall. Advanced age was not predictive of all-cause hospitalization, except for mild associations in the HF-BREF group and at age ≥85 years in the HF-REF group.
We found that multivariable models for each of the 3 outcomes were highly consistent across HF-PEF, HF-BREF, and HF-REF patients (Figure 1 ; complete data included as tables in the online-only Data Supplement). In simplified interaction models ( 
Discussion
Within a large, contemporary, multicenter cohort of patients with HF, we found that commonly available risk factors carried surprisingly similar prognostic information for a variety of outcomes across all LVEF categories. Despite the existence of a variety of published HF risk models, this systematic assessment of relative risk factor performance across 3 LVEF strata for death, HF-related hospitalization, and all-cause hospitalization within a diverse, representative HF population provides novel HF risk information. For example, the popularized Seattle Heart Failure Model 4 was derived and validated in randomized trial populations of patients with HF-REF.
Its performance has subsequently been tested in a variety of other cohorts, including patients with a range of LVEF, 21, 22 but this piece-meal approach makes comparisons of individual risk factor performance across different LVEF categories more difficult. Others have begun to look at the comparative prognostic performance of single risk factors by LVEF categories, such as a recent analysis showing that for a given serum B-type natriuretic peptide level the prognosis is essentially the same for patients with HF-PEF as those with HF-REF. 23 Here, the analytic approach was specifically designed to provide information on comparative risk factor performance across a wide range of covariates by LVEF categories. We essentially found that none of the risk factors consistently interacted with LVEF.
Although LVEF dictates responsiveness to certain HF therapies, 24 our data demonstrate that common risk factors have quite similar prognostic performance across major strata of LVEF. The number of statistically significant differences in risk factor performance across LVEF strata in our models was not much different than would have been predicted by chance alone. We conclude that a parsimonious approach to HF risk modeling is appropriate in most circumstances, at least for discrimination among singular end points. This may have important practical implications for HF risk stratification efforts, particularly because LVEF has been difficult to automatically extract from most electronic medical records without manual chart review.
Our findings extend those of previous HF risk studies, particularly into the population of patients with HF-PEF and HF-BREF. Our results are consistent with several smaller studies of hospitalized patients with HF-PEF, which have observed higher risks of hospitalization in patients with diabetes mellitus, depressive symptoms, and anemia. [25] [26] [27] 
Potential Limitations
Because of the large sample size, some associations within individual risk models may be statistically significant but not clinically meaningful. More important, even with the relative power of this sample size, we found strikingly few statistically and even fewer clinically significant differences between risk models, strengthening the primary conclusion that risk factor and overall model performance was quite similar within LVEF strata. Second, insured populations in our participating health plans may not be fully representative of the general population. Nevertheless, the breadth of geographic and demographic diversity represented across 4 geographically diverse health plans, as well as the community-based nature of healthcare delivery, suggests that findings from our cohort are likely to be highly generalizable to HF patients with any level of LVEF in real-world practice settings. This is in stark contrast to previously reported studies focused on highly selected patient samples enrolled into clinical trials or referral-based tertiary care academic medical centers. Finally, model construction did not include an exhaustive list of all previously known risk factors for adverse outcomes in HF. For example, measures of renal function, natriuretic peptide levels, and medication use were absent from the list of independent variables. Unlike the construction of risk models for clinical use where the goal is to optimize prognostic performance, the purpose of this analysis was to compare the relative performance of a variety of predictor variables across clinically important LVEF categories for common clinical end points. Although inclusion of additional predictor variables may have led to quantitative adjustments in the reported adjusted hazards ratios (eg, degree of association of anemia in a model with and without a measure of kidney dysfunction), meaningful relative comparisons across LVEF strata and clinical outcomes should qualitatively not be contingent on a single variable. In addition, both natriuretic peptide levels and measures of renal function have been shown to be strongly predictive in both HF-PEF and HF-REF populations such that their addition to the current analysis would not be expected to disrupt the overall symmetry seen with the current list of covariates. 23
Conclusion
This study systematically assessed predictor covariate performance across clinically important LVEF strata for relevant clinical outcomes. We found that in a large contemporary HF population, despite important therapeutic distinctions currently dictated by LVEF, risk assessment was strikingly similar regardless of LVEF. These data suggest that HF risk models using traditional risk markers can be applied to broad HF populations.
